Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25938820 | 0.99 | TOP1 (0.54) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL30518715 | 0.89 | TOP1 (0.57) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL25932927 | 0.89 | TOP1 (0.57) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL25950524 | 0.89 | TOP1 (0.54) | TOP1MEN1KMT2A | |
| SCHEMBL25330069 | 0.88 | TOP1 (0.58) | TOP1MEN1KMT2A | |
| SCHEMBL30518753 | 0.83 | TOP1 (0.52) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL25941428 | 0.83 | TOP1 (0.52) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL25331495 | 0.82 | TOP1 (0.60) | TOP1MEN1KMT2ASLC2A1 | |
| SCHEMBL30409333 | 0.81 | TOP1 (0.67) | TOP1MEN1KMT2A | |
| SCHEMBL23963966 | 0.80 | TOP1 (0.65) | TOP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426727-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2022078524-A4 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | TOP1 3/4885MEN1 188/4885KMT2A 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.